Group 1 - The company, Fangda Holdings (01521.HK), has announced a board meeting scheduled for August 28, 2025, to consider and approve its interim results for the six months ending June 30, 2025, as well as to discuss the potential declaration of an interim dividend, if any [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 方達控股公司*（「本公司」）董事會（「董事會」）茲通告謹定於2025年8月28日（星期 四）舉行董事會會議，以（其中包括）考慮及通過本公司及其附屬公司截至2025年6 月30日止六個月的中期業績，及考慮派付中期股息（如有）。 承董事會命 方達控股公司* 主席 李松博士 香港，2025年8月15日 * 僅供識別 FRONTAGE HOLDINGS CORPORATION 方達控股公司* （於開曼群島註冊成立的有限公司） （股份代號：1521） 董事會召開日期 截至本公告日期，董事會成員包括執行董事李松博士、Wentao Zhang博士及 Zhongping Lin博士；非執行董事Yin Zhuan女士及吳灝先生；及獨立非執行董事 李軼梵先生、劉二飛先生及王勁松博士。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 FRONTAGE HOLDINGS CORPORATION 方達控股公司* （於開曼群島註冊成立的有限公司） （股份代號：1521） 持續關連交易 修訂有關經重續服務框架協議的年度上限 概要 茲提述本公司日期為2024年8月28日的公告，內容有關本公司與杭州泰格訂立 的經重續服務框架協議。 鑒於本集團與杭州泰格之間的企業需求不斷增加，董事會預期，經重續服務框 架協議的原有年度上限將不足夠。於2025年8月6日，董事會議決修訂截至2027 年12月31日止三個年度各年、就本集團根據經重續服務框架協議提供相關服務 的持續關連交易的年度上限。 上市規則之涵義 於本公告日期，杭州泰格為控股股東，故為本公司的關連人士。因此，根據上 市規則第十四A章，經重續服務框架協議項下擬進行的交易構成本公司的持續關 連交易。 根據最高經修訂購買年度上限，由於本集團根據經重續服務框架協議就泰格集 團提供相關服務將支付的費用的年度 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 方達控股公司 (於開曼群島註冊成立的有限公司) 呈交日期: 2025年8月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01521 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 USD | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 USD | | 50,000 | 本月底法定/註冊股本總 ...

Market Performance - The Hong Kong stock market showed mixed performance with the Hang Seng Index rising by 0.68% to 25,562.13 points, while the Tech Index fell by 0.24% to 5,664.02 points, and the National Enterprises Index increased by 0.29% to 9,177.15 points [2][3]. Hang Seng Index Movement - The Hang Seng Index reached a high of 25,660.54 points in the morning but maintained a volatile pattern before closing slightly higher [4]. Sector Performance - Insurance, pharmaceuticals, and brokerage stocks saw collective strength, while coal, shipping, and photovoltaic stocks experienced adjustments [5]. Insurance Sector Strength - Major insurance stocks like AIA Group (up 4.96%), China Pacific Insurance (up 3.91%), and Ping An Insurance (up 3.49%) saw significant gains due to a favorable assessment of life insurance reserve interest rates, which are expected to lower the new business liability costs for insurers [6][7]. Pharmaceutical Sector Boost - Pharmaceutical stocks surged, with companies like Fonda Holdings (up 10.39%), Zhaoyan New Drug (up 6.76%), and Via Biotechnology (up 5.45%) benefiting from overseas licensing deals, including a notable $12.5 billion collaboration between Hengrui Medicine and GlaxoSmithKline [8][9]. Brokerage Sector Gains - Brokerage stocks such as Guotai Junan International (up 9.45%), Shenwan Hongyuan Hong Kong (up 7.32%), and Xingzheng International (up 5.08%) experienced strong performance, likely influenced by the upcoming implementation of the Stablecoin Regulation in Hong Kong [11][13]. Weakness in Cyclical Stocks - Coal, shipping, and photovoltaic stocks faced declines, with companies like Feishang Non-Ferrous Coal (down 15.28%) and COSCO Shipping Ports (down 10.99%) leading the downturn due to falling commodity prices in the futures market [14][18]. Individual Stock Movements - Xuanwu Cloud saw a significant increase of 28% following a strategic partnership with LG Uplus, while Zhejiang United Investment surged by 116.67% on expectations of turning a profit by April 2025 [23][24].

Group 1 - CRO concept stocks experienced a strong performance in early trading, with notable gains from companies such as Fonda Holdings (+14.49%), Kanglong Chemical (+7.9%), and King’s Ray Biotechnology (+7.17%) [1] - Medpace, an overseas CRO company, saw its stock price jump over 44% at the opening, reaching a peak increase of 62.3% before closing with a nearly 54.7% rise, marking its highest closing record and the largest single-day increase since its listing nearly nine years ago [1] - Medpace's Q2 financial report indicated a revenue and EBITDA growth of over 10% year-on-year, exceeding analyst expectations by more than 11%, and the company raised its revenue and profit guidance for the year by at least 11% [1] Group 2 - Zhongtai Securities reported that WuXi AppTec and Boteng Co. released mid-year performance forecasts, with WuXi AppTec's adjusted net profit for the first half of 2025 expected to be approximately 6.31 billion yuan, reflecting a 44% year-on-year increase [2] - The CRO and CDMO sectors are anticipated to gradually recover due to multiple factors, including the onset of overseas interest rate cuts in Q4 2024, improved pessimistic expectations from geopolitical negotiations in Q2 2025, and the implementation of major domestic innovative drug projects and policies since 2025 [2] - The combination of recovering demand and a supply-side clean-up over the past three years is expected to lead to a "Davis Double Play" in profitability and valuation for the sector, suggesting significant investment opportunities [2]

Group 1 - The Hong Kong pharmaceutical stocks have shown strong performance, with Fangda Holdings (01521.HK) rising by 23.19%, Clover Biopharmaceuticals-B (02197.HK) increasing by 17.65%, Lepu Biopharma-B (02157.HK) up by 11.25%, and WuXi AppTec (02268.HK) gaining 9.41% [1] - WuXi AppTec is expected to see a more than 67% growth in adjusted net profit for the mid-term [1]

Financial Performance - Revenue for the year ended December 31, 2024, is approximately $254.9 million, a decrease of 1.9% from approximately $259.9 million for the year ended December 31, 2023[14]. - Adjusted net profit for the year ended December 31, 2024, is projected to be $13.243 million, down from $23.974 million for the year ended December 31, 2023[9]. - The gross profit margin for the year ended December 31, 2024, is projected to be 27.4%, a decrease from 30.2% for the year ended December 31, 2023[9]. - The adjusted net profit margin for the year ended December 31, 2024, is projected to be 5.2%, down from 9.2% for the year ended December 31, 2023[9]. - The company's revenue decreased by 1.9% from approximately $259.9 million for the year ended December 31, 2023, to approximately $254.9 million for the year ended December 31, 2024[26]. - Revenue from North America and Europe decreased by 0.5% from approximately $199.1 million to approximately $198.2 million for the same periods[62]. - Revenue from the Chinese market decreased by 5.9%, from approximately RMB 428.9 million (approximately $60.8 million) to approximately RMB 403.5 million (approximately $56.7 million)[62]. - The decline in revenue was primarily due to decreased earnings from drug development and discovery services, influenced by a weak global investment environment in the biopharmaceutical sector[62]. - Gross profit decreased by 11.0% to approximately $69.8 million in 2024, with a gross margin of 27.4%, down from 30.2% in 2023[68]. - Adjusted net profit for the year ended December 31, 2024, was approximately $13.2 million, a decrease of 45.0% from $24.0 million in 2023[78]. Future Revenue and Growth - Future contracted revenue as of December 31, 2024, reached approximately $390.6 million, an increase of 14.1% from approximately $342.2 million as of December 31, 2023[14]. - The company aims to enhance service capabilities through organic growth and strategic acquisitions, ensuring comprehensive and high-quality services for global clients[27]. - The global contract research organization market is projected to grow from $83.49 billion in 2024 to $192.68 billion by 2032, with a CAGR of 11.1%[58]. - The company aims to leverage its over 20 years of experience to address complex regulatory issues and provide comprehensive solutions in the evolving market[59]. Operational Developments - In 2024, the company expanded its headquarters in Exton, Pennsylvania, adding 46,300 square feet of life sciences space, increasing total space to over 200,000 square feet, enhancing biorepository capabilities[17]. - The company established a leading high-throughput screening platform in Wuhan, China, significantly improving R&D efficiency and reducing project delivery times[17]. - The clinical sample production facility in Suzhou, covering 89,000 square feet, has been fully completed and equipped with intelligent production lines for oral solid preparations, sterile injections, and semi-solid external preparations[39]. - The company has established a full-service system in China covering drug discovery, preclinical research, and clinical research[38]. - The company successfully completed the cross-species pharmacokinetics study for the world's first PRMT5 inhibitor, delivering key data packages for regulatory submissions in both China and the U.S.[40]. Leadership and Management - The company appointed Mr. Gao Jun as President of the Asia-Pacific region and Chief Financial Officer, effective January 2, 2024, and February 1, 2024, respectively[15]. - Dr. Wentao Zhang and Dr. Zhongping Lin were appointed as co-CEOs, marking a significant leadership transition aimed at enhancing the company's leadership and driving growth and innovation[16]. - The management team includes experienced professionals with backgrounds in pharmaceuticals and biostatistics, contributing to the company's strategic direction[106][107][108]. - The management team emphasizes the importance of recruiting and retaining talent through targeted training programs[103]. Employee and Talent Management - As of December 31, 2024, the group has a total of 1,560 employees, with 839 located in North America and 721 in China[101]. - Employee costs for the year ended December 31, 2024, were approximately $114.6 million, compared to $112.2 million for the year ended December 31, 2023, reflecting a year-over-year increase of about 2.1%[101]. - Approximately 84% of employees hold a bachelor's degree or higher, with 562 employees possessing advanced degrees[101]. - The group has implemented several stock incentive plans, including pre-IPO stock incentive plans and 2018 and 2021 stock incentive plans, to reward contributions from eligible participants[103]. Compliance and Governance - The company is committed to compliance with applicable laws and regulations, ensuring mandatory training in various technical and safety areas[103]. - The board of directors includes a mix of executive and non-executive members, with specific terms for rotation and re-election outlined[150]. - The company has arranged appropriate directors' and officers' liability insurance for its directors and senior management during the reporting period[161]. - The board believes that all independent non-executive directors are independent individuals as per the annual confirmation received[154]. Shareholder Information - The board has decided not to recommend any final dividend for the reporting period[136]. - The group has adopted a dividend policy to allow shareholders to participate in profit distribution while retaining sufficient reserves for future growth[135]. - As of December 31, 2024, the total distributable reserves available for shareholders amounted to approximately $107.3 million[143]. - Sales to the top five customers accounted for approximately 14.6% of the total revenue, with the largest customer contributing about 5.0%[148]. Stock Options and Incentive Plans - The company has a stock option plan with a total of 53,360,000 unexercised options as of December 31, 2024[175]. - The exercise price of unexercised stock options ranges from $0.049 to $0.057[179]. - The total number of stock options granted during the reporting period was 4,500,000 shares at an exercise price of HKD 0.820[197]. - The company aims to attract and retain skilled individuals through the 2018 Share Incentive Plan to promote shareholder interests[185].

Financial Performance - Total revenue for 2024 was $254.9 million, a decrease of 1.9% from $259.9 million in 2023[3] - Gross profit for 2024 was $69.8 million, down 11.0% from $78.4 million in 2023, resulting in a gross margin of 27.4%[3] - Net profit for 2024 plummeted to $0.6 million, a decline of 94.4% compared to $10.7 million in 2023, leading to a net profit margin of 0.2%[3] - Adjusted EBITDA for 2024 was $54.0 million, down 14.6% from $63.2 million in 2023, with an adjusted EBITDA margin of 21.2%[3] - Basic earnings per share (EPS) for 2024 was $0.0004, a decrease of 92.5% from $0.0053 in 2023[3] - The company's revenue decreased by 1.9% from approximately $259.9 million for the year ended December 31, 2023, to approximately $254.9 million for the year ended December 31, 2024[52] - The group's revenue decreased by 1.9% from approximately $259.9 million for the year ended December 31, 2023, to approximately $254.9 million for the year ending December 31, 2024[77] - The group's gross profit decreased by 11.0% from approximately $78.4 million for the year ended December 31, 2023, to approximately $69.8 million for the year ended December 31, 2024, with a gross margin decline from 30.2% to 27.4%[81] - Net profit dropped from approximately $10.7 million for the year ended December 31, 2023, to approximately $0.6 million for the year ended December 31, 2024, with a net profit margin decline from 4.1% to 0.2%[89] Revenue Breakdown - Revenue from the Drug Discovery segment was $31.2 million, down 6.9% from $33.5 million in 2023[18] - Revenue from the Drug Development segment was $81.9 million, a decrease of 13.7% from $95.1 million in 2023[18] - Revenue from the Laboratory Testing segment increased to $132.5 million, up 7.6% from $123.7 million in 2023[18] - Revenue from North America and Europe was $198.2 million, while revenue from China was $56.7 million, contributing to the total revenue[23] - Revenue from drug discovery decreased from approximately $33.5 million to approximately $31.2 million, while revenue from drug development decreased from approximately $95.1 million to approximately $81.9 million[78] - Revenue from China decreased by 5.9% from approximately RMB 428.9 million (approximately $60.8 million) to approximately RMB 403.5 million (approximately $56.7 million)[77] Expenses and Costs - Research and development expenses for 2024 were $5.6 million, slightly reduced from $6.0 million in 2023[5] - Selling and marketing expenses increased by 3.7% from approximately $8.2 million for the year ended December 31, 2023, to approximately $8.5 million for the year ended December 31, 2024, due to increased marketing and business development efforts[84] - Administrative expenses rose by 5.6% from approximately $44.6 million for the year ended December 31, 2023, to approximately $47.1 million for the year ended December 31, 2024, largely due to the consolidation of Nucro and Frontage Europe[85] - Financial costs increased by 35.2% from approximately $7.1 million for the year ended December 31, 2023, to approximately $9.6 million for the year ended December 31, 2024, due to increased borrowing for expansion and operations[87] Assets and Liabilities - Total assets decreased to $553.6 million in 2024 from $571.9 million in 2023[7] - The company's cash and cash equivalents decreased to approximately $44.1 million as of December 31, 2024, down from $53.2 million in 2023, attributed to payments for property, plant, and equipment[101] - The company's asset-liability ratio increased to 33.0% as of December 31, 2024, compared to 26.2% in 2023, mainly due to significant financing activities to support business expansion[107] - The company's lease liabilities decreased to approximately $58.7 million as of December 31, 2024, from $63.7 million in 2023[104] Shareholder Actions - The board of directors did not recommend any final dividend for the reporting period[3] - The company repurchased 50,788,000 shares at a cost of $11,203 thousand in 2024, compared to 15,848,000 shares at a cost of $4,231 thousand in 2023[48] - The company is committed to creating long-term value for shareholders through its share repurchase program, reflecting confidence in its business outlook[113] Strategic Initiatives - The company has restructured its operations into two main divisions: Global Drug Discovery and Development Services, and Global Laboratory Services[15][16] - The strategic adjustment aims to enhance operational efficiency and promote innovation across all business segments[16] - The company aims to enhance service capabilities through organic growth and strategic acquisitions despite macroeconomic fluctuations[53] - The company plans to invest RMB 200 million in new technology development to improve operational efficiency[124] Market Position and Growth - North America holds a 35% market share in the global contract research organization services market, maintaining the company's leading position[54] - The global contract research organization market is projected to grow from $83.49 billion in 2024 to $192.68 billion by 2032, with a CAGR of 11.1%[75] - The company is expanding its market presence in Southeast Asia, targeting a 15% market share by the end of 2025[124] Research and Development - The company established a liposome complex structure analysis system for the world's first liposome T cell engager drug, aiding in its clinical approval[63] - The company enhanced its ADC analysis platform and launched comprehensive biomarker testing services to support new drug development in the biopharmaceutical sector[64] - The Drug Metabolism and Pharmacokinetics Department expanded its product offerings to meet the growing demand from clients for complex discovery and development projects, with successful human absorption, metabolism, and excretion studies using 14C labeled drug substances in 2024[56] Compliance and Governance - The company has adhered to the corporate governance code principles applicable to it during the reporting period[115] - The audit and risk management committee reviewed the accounting principles and policies adopted by the group, confirming that the audited consolidated financial statements fairly reflect the group's financial position and performance for the reporting period[116] - The company adheres to international financial reporting standards, ensuring transparency and accuracy in financial reporting[124]

Financial Performance - Revenue for the six months ended June 30, 2024, was $128,475 thousand, a slight increase from $128,356 thousand in the same period of 2023[7]. - Gross profit decreased to $34,842 thousand, down from $38,988 thousand year-over-year, resulting in a gross margin of 27.1% compared to 30.4% in 2023[7]. - The company reported a net loss of $300 thousand for the first half of 2024, contrasting with a profit of $4,558 thousand in the same period last year[7]. - Adjusted net profit for the period was $6,147 thousand, down from $10,223 thousand in 2023, reflecting an adjusted net profit margin of 4.8% compared to 8.0%[7]. - Total comprehensive loss for the period was $2,973 thousand, compared to a comprehensive income of $1,219 thousand in 2023, marking a shift from profit to loss[160]. - The company recorded a net loss of approximately $0.3 million for the six months ended June 30, 2024, compared to a net profit of approximately $4.6 million for the same period in 2023[56]. - Adjusted net profit decreased by 40.2% from approximately $10.2 million to approximately $6.1 million, with an adjusted net profit margin of 4.8% compared to 8.0% in the previous year[61]. - Basic and diluted loss per share was $0.0001 for the six months ended June 30, 2024, compared to earnings of $0.0023 and $0.0022 for the same period in 2023[64]. Assets and Liabilities - Total assets as of June 30, 2024, were $569,024 thousand, a slight decrease from $571,869 thousand at the end of 2023[7]. - Total equity decreased to $337,397 thousand from $345,147 thousand at the end of 2023, while total liabilities increased to $231,627 thousand from $226,722 thousand[7]. - Cash and cash equivalents were reported at $42,998 thousand, down from $53,186 thousand at the end of 2023[7]. - Non-current assets as of June 30, 2024, amounted to $421,799 thousand, a decrease from $430,305 thousand as of December 31, 2023, representing a decline of 2.4%[161]. - Current assets increased to $147,225 thousand as of June 30, 2024, compared to $141,564 thousand at the end of 2023, showing a growth of 4.7%[161]. - Total liabilities decreased to $115,348 thousand as of June 30, 2024, down from $99,580 thousand at the end of 2023, indicating a reduction of 15.9%[162]. - The company's net assets as of June 30, 2024, were $337,397 thousand, a decrease from $345,147 thousand as of December 31, 2023, reflecting a decline of 2.3%[162]. Revenue Breakdown - Revenue from North America and Europe decreased by 0.6% from approximately $100.0 million to approximately $99.4 million during the same period, primarily due to a decline in drug development and discovery services[40]. - Revenue from China increased by 4.4% from approximately RMB 197.8 million (approximately $28.4 million) to approximately RMB 206.5 million (approximately $29.1 million) due to marketing efforts and improved project execution[40]. - Laboratory testing services generated $66.3 million in revenue for 2024, up from $58.5 million in 2023, reflecting a significant increase[41]. - Drug development revenue decreased to $42,797 thousand from $47,097 thousand, a decline of 9.2% compared to the previous year[177]. - Drug discovery services reported revenue of $15,820 thousand, down from $18,524 thousand, indicating a decrease of 14.6% year-over-year[177]. - The pharmaceutical product development segment generated $3,603 thousand, a decrease from $4,242 thousand, reflecting a decline of 15.1% compared to the same period last year[177]. Operational Developments - The company completed the acquisition of Accelera's bioanalytical and drug metabolism and pharmacokinetics business in January 2024, enhancing its service offerings in Europe[22]. - The operational restructuring in 2023 led to the establishment of two main divisions: Global Drug Discovery and Development Services and Global Laboratory Services, aimed at improving efficiency and service integration[19]. - The company has expanded its safety and toxicology department in Chicago, reducing reliance on external partners and enhancing internal capabilities[19]. - The integration of Accelera's services is expected to enhance the company's capabilities and introduce new services to better meet customer needs in Europe[22]. - The company aims to leverage advanced technology and new services to strengthen support for drug development and research services, driving sustainable growth[22]. - The restructuring and service integration are designed to better respond to the evolving demands of the biopharmaceutical industry in 2024[19]. Cost Management and Expenses - Service costs increased by 4.7% from approximately $89.4 million to approximately $93.6 million, mainly due to additional costs from Nucro and Frontage Europe[45]. - Sales and marketing expenses increased by 17.5% from approximately $4.0 million to approximately $4.7 million, attributed to enhanced marketing and business development efforts[49]. - Administrative expenses rose by 7.0% from approximately $22.9 million to approximately $24.5 million, primarily due to the integration of Nucro and Frontage Europe into the consolidated financial statements[52]. - Research and development expenses decreased by 9.7% from approximately $3.1 million to approximately $2.8 million, due to cost reduction measures[53]. - Financial costs increased by 38.7% from approximately $3.1 million to approximately $4.3 million, driven by increased borrowing for expansion and operations[54]. Shareholder Information - The board has decided not to declare an interim dividend for the six months ended June 30, 2024[7]. - The company repurchased a total of 48,410,000 shares at a total cost of approximately HKD 85,849,860 during the six months ending June 30, 2024[82]. - Major shareholders include Hong Kong Tiger with 1,032,964,090 shares (50.74%) and Hangzhou Tiger with 1,258,984,090 shares (61.84%) as of June 30, 2024[96]. - The total number of outstanding shares is 2,035,724,910, with no other significant shareholders disclosed[96]. - The remuneration for Executive Director Dr. Li Song has been adjusted to USD 368,000 per year, effective September 1, 2024[88]. - The remuneration for CEO Dr. Abdul Mutlib has been adjusted to USD 625,000 per year, effective September 1, 2024[88]. Market Trends and Industry Outlook - The global contract research organization market is estimated to be valued between $48.19 billion and $82.55 billion in 2023, projected to reach up to $148.76 billion by 2028[16]. - In 2024, the global and Chinese biopharmaceutical industry continues to experience cyclical downturns, with overall growth remaining slow despite signs of increased financing for biopharmaceutical companies[23]. - The company continues to focus on optimizing its cost structure and promoting technological innovation to navigate market challenges[16].